Saint Paul Les Dax

This research aims to evaluate the real-life effectiveness, safety, usage, tolerance, and satisfaction of four CE-marked isotonic and hypertonic seawater-based nasal sprays. It focuses on infants, children, adults, and pregnant or breastfeeding women who suffer from acute and chronic sinonasal conditions such as upper respiratory tract infections, COVID-19, bronchiolitis, allergic rhinitis, chronic rhinosinusitis, and post-surgery recovery. The study seeks to answer key questions on how well these nasal sprays work and how safe and satisfactory they are in everyday use. Participants will use one of four nasal sprays designed for different age groups and indications. The sprays are applied by spraying 1 to 3 seconds into each nostril multiple times daily, depending on the product and condition. Treatment for nasal symptoms ranges from 2 to 6 times a day, while hygiene and prevention uses are less frequent. The nasal sprays are used according to their intended purpose and population, including special instructions for babies, children, and adults. During the study, participants or their parents/caregivers will perform nasal washes following healthcare provider advice and complete online questionnaires about their symptoms and experience. Researchers will monitor nasal symptom improvement over 5 days for acute conditions and up to 14 days for chronic conditions. The study includes assessments of nasal symptom intensity, nasal breathing impairment, safety, and user satisfaction. Participants are expected to comply with study requirements for up to 3 months and have daily internet access for questionnaire completion.

Hemiparesis is a common movement disorder following a stroke, where many patients struggle to regain functional use of their affected upper limb. Researchers are evaluating whether using mirror therapy through an Intensive Visual Simulation (IVS) device can improve motor function and abilities in the affected hand and wrist during the sub-acute phase of stroke, between 4 and 10 weeks after the event. This study is a randomized controlled trial comparing IVS therapy to conventional rehabilitation care for patients with moderate to severe hemiparesis. The IVS3 device creates an immersive mirror therapy experience by filming the unaffected upper limb and projecting its mirrored image onto a screen above the affected arm, creating the illusion of movement in the paralyzed limb. Participants receive 6 weeks of treatment where part of their routine occupational therapy is replaced with structured movement repetition programs using the IVS3 device. The therapy progresses from observation and mental practice in the first week to analytical wrist and finger movements in weeks two and three, and then functional tasks like object manipulation and gripping from week four onward. The control group receives conventional upper limb rehabilitation involving stretching, postural exercises, assisted and active movements, and gripping tasks. Participants are involved in treatment sessions over 6 weeks, starting between 4 and 10 weeks after stroke. Researchers assess motor performance using the Fugl-Meyer wrist/hand sub-score at the start and end of the program to measure changes. The study lasts 18 weeks per participant and includes monitoring for any discomfort or fatigue during device use. No major risks beyond daily life activities are expected. The study aims to determine if the IVS device can enhance motor recovery and functional use of the affected upper limb compared to standard rehabilitation alone.